This activity expired on October 26, 2023; credit is no longer available.

Clinical Conundrums in Pretreated Metastatic Urothelial Carcinoma: Improving Patient Outcomes With Novel Antibody-Drug Conjugates

Media: Enduring Material
Activity Release Date: October 27, 2022
Activity Expiration Date: October 26, 2023
Time to Complete Activity: 45 minutes

Activity Description

Metastatic urothelial carcinoma (UC) is a devastating illness with limited treatment options, especially for patients who have been previously treated with platinum-based chemotherapy and anti–PD-1/L1 therapy. This educational activity features two experts in a lively discussion about this rapidly evolving treatment landscape. The activity also features a patient and his caregiver’s perspective on their first-hand experience with the treatment strategies and his journey.
These experts review the latest data and ongoing research on platinum-based chemotherapy, antibody–drug conjugates, and pan-FGFR inhibitors for the treatment of bladder cancer and discuss the management of adverse events associated with novel therapeutics.

Target Audience

This activity has been designed to meet the educational needs of oncologists, advanced practice oncology clinicians (NPs and PAs), oncology nurses, and other interprofessional cancer care team members who manage patients with urothelial carcinoma (UC)

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Integrate novel antibody-drug conjugates (ADCs) into individualized management plans for appropriate patients with metastatic UC, taking into consideration treatment history, latest clinical evidence, and current guideline recommendations
• Implement team-based strategies to monitor for and manage treatment-related adverse events that may occur in patients with metastatic UC who are receiving novel ADCs as part of their care
• Apply an interprofessional team-based approach to care for patients with metastatic UC that incorporates shared decision-making, appropriate patient education and counseling, and effective interprofessional collaboration and care coordination

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Scott T. Tagawa, MD, MS, FACP
Professor of Medicine & Urology
Meyer Cancer Center
Weill Cornell Medicine
New York, New York

Scott T. Tagawa, MD, MS, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AAA/Novartis Pharmaceuticals Corporation; AbbVie Inc.; AIkido Pharma Inc.; Amgen Inc.; Astellas Pharma US, Inc.; Bayer Corporation; Blue Earth Diagnostics; Clarity Pharmaceuticals; Clovis Oncology; Convergent Therapeutics, Inc.; Dendreon Pharmaceuticals LLC; EMD Serono, Inc.; Eisai Inc.; Endocyte; Genentech, Inc.; Genomic Health, Inc.; Immunomedics, Inc.; Janssen Pharmaceuticals, Inc.; Karyopharm; Medivation, Inc.; Myovant Sciences Ltd.; Pfizer; POINT Biopharma Global Inc.; QED Therapeutics, Inc.; sanofi-aventis U.S. LLC; Seattle Genetics, Inc.; Telix Pharmaceuticals Limited; and Tolmar Pharmaceuticals, Inc.
Grant/Research Support from AbbVie Inc.; Amgen Inc.; Astellas Pharma US, Inc.; AstraZeneca; ATLAB Pharma; AVEO Pharmaceuticals, Inc.; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Clovis Oncology; Dendreon Pharmaceuticals LLC; Endocyte; Genentech, Inc.; Gilead Sciences, Inc.; Immunomedics, Inc.; INOVIO Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Karyopharm; Lilly; Medivation, Inc.; Merck & Co., Inc.; Millennium Pharmaceuticals, Inc; NewLink Genetics; Novartis Pharmaceuticals Corporation; POINT Biopharma Global Inc.; Progenics Pharmaceuticals, Inc.; Rexahn Pharmaceuticals; sanofi-aventis U.S. LLC; and Seattle Genetics, Inc.
Stock Shareholder in AIkido Pharma Inc.
Other Financial or Material Support Patent for Gilead Sciences, Inc.; Immunomedics, Inc.; and Weill Medical College.

Faculty/Planner
Amie Patel, RN, BSN, MS, CCRC
Research Nurse Specialist
Genitourinary Oncology
Meyer Cancer Center
Weill Cornell Medical Center
New York Presbyterian Hospital
New York, New York

Amie Patel, RN, BSN, MS, CCRC, has no financial interests/relationships or affiliations in relation to this activity.

Patient/Planner
Rosario Ardizzone

Rosario Ardizzone has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This program has been supported by an independent educational grant from Gilead Sciences, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit^TM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

This activity expired on October 26, 2023; credit is no longer available.

Clinical Conundrums in Pretreated Metastatic Urothelial Carcinoma: Improving Patient Outcomes With Novel Antibody-Drug Conjugates

Media: Enduring Material
Activity Release Date: October 27, 2022
Activity Expiration Date: October 26, 2023
Time to Complete Activity: 45 minutes

Activity Description

Metastatic urothelial carcinoma (UC) is a devastating illness with limited treatment options, especially for patients who have been previously treated with platinum-based chemotherapy and anti–PD-1/L1 therapy. This educational activity features two experts in a lively discussion about this rapidly evolving treatment landscape. The activity also features a patient and his caregiver’s perspective on their first-hand experience with the treatment strategies and his journey.
These experts review the latest data and ongoing research on platinum-based chemotherapy, antibody–drug conjugates, and pan-FGFR inhibitors for the treatment of bladder cancer and discuss the management of adverse events associated with novel therapeutics.

Target Audience

This activity has been designed to meet the educational needs of oncologists, advanced practice oncology clinicians (NPs and PAs), oncology nurses, and other interprofessional cancer care team members who manage patients with urothelial carcinoma (UC)

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Integrate novel antibody-drug conjugates (ADCs) into individualized management plans for appropriate patients with metastatic UC, taking into consideration treatment history, latest clinical evidence, and current guideline recommendations
• Implement team-based strategies to monitor for and manage treatment-related adverse events that may occur in patients with metastatic UC who are receiving novel ADCs as part of their care
• Apply an interprofessional team-based approach to care for patients with metastatic UC that incorporates shared decision-making, appropriate patient education and counseling, and effective interprofessional collaboration and care coordination

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Scott T. Tagawa, MD, MS, FACP
Professor of Medicine & Urology
Meyer Cancer Center
Weill Cornell Medicine
New York, New York

Scott T. Tagawa, MD, MS, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AAA/Novartis Pharmaceuticals Corporation; AbbVie Inc.; AIkido Pharma Inc.; Amgen Inc.; Astellas Pharma US, Inc.; Bayer Corporation; Blue Earth Diagnostics; Clarity Pharmaceuticals; Clovis Oncology; Convergent Therapeutics, Inc.; Dendreon Pharmaceuticals LLC; EMD Serono, Inc.; Eisai Inc.; Endocyte; Genentech, Inc.; Genomic Health, Inc.; Immunomedics, Inc.; Janssen Pharmaceuticals, Inc.; Karyopharm; Medivation, Inc.; Myovant Sciences Ltd.; Pfizer; POINT Biopharma Global Inc.; QED Therapeutics, Inc.; sanofi-aventis U.S. LLC; Seattle Genetics, Inc.; Telix Pharmaceuticals Limited; and Tolmar Pharmaceuticals, Inc.
Grant/Research Support from AbbVie Inc.; Amgen Inc.; Astellas Pharma US, Inc.; AstraZeneca; ATLAB Pharma; AVEO Pharmaceuticals, Inc.; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Clovis Oncology; Dendreon Pharmaceuticals LLC; Endocyte; Genentech, Inc.; Gilead Sciences, Inc.; Immunomedics, Inc.; INOVIO Pharmaceuticals; Janssen Pharmaceuticals, Inc.; Karyopharm; Lilly; Medivation, Inc.; Merck & Co., Inc.; Millennium Pharmaceuticals, Inc; NewLink Genetics; Novartis Pharmaceuticals Corporation; POINT Biopharma Global Inc.; Progenics Pharmaceuticals, Inc.; Rexahn Pharmaceuticals; sanofi-aventis U.S. LLC; and Seattle Genetics, Inc.
Stock Shareholder in AIkido Pharma Inc.
Other Financial or Material Support Patent for Gilead Sciences, Inc.; Immunomedics, Inc.; and Weill Medical College.

Faculty/Planner
Amie Patel, RN, BSN, MS, CCRC
Research Nurse Specialist
Genitourinary Oncology
Meyer Cancer Center
Weill Cornell Medical Center
New York Presbyterian Hospital
New York, New York

Amie Patel, RN, BSN, MS, CCRC, has no financial interests/relationships or affiliations in relation to this activity.

Patient/Planner
Rosario Ardizzone

Rosario Ardizzone has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This program has been supported by an independent educational grant from Gilead Sciences, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit^TM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

This activity expired on October 16, 2023; credit is no longer available.

Breaking Down Barriers to Treatment Adherence and Persistence in HR+/HER2- Early Breast Cancer

Media: Enduring Material
Activity Release Date: October 17, 2022
Activity Expiration Date: October 16, 2023
Time to Complete Activity: 60 minutes

Activity Description

Oral anticancer therapies, including CDK4/6 inhibitors, are well established in the treatment of HR+/HER2- advanced breast cancer and, with the recent approval of abemaciclib for the treatment of HR+/HER2- early breast cancer, have now moved into earlier disease settings. This activity features strategies for risk assessment and individualized treatment selection for patients with HR+/HER2- early breast cancer, as well as best practices for improving adherence and persistence to ensure patients stay on prescribed therapy by providing patient education, guidance, and appropriately monitoring and managing treatment-related adverse events.

Target Audience

This activity has been designed to meet the educational needs of oncologists, oncology staff nurses, advanced practice nurses, nurse navigators, and other care team professionals who manage patients with HR+/HER2- early breast cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Review the mechanism of action, latest safety and efficacy data, and clinical role of currently approved CDK4/6 inhibitors in HR+/HER2- early breast cancer
• Describe disease-, treatment-, management-, patient-related, and other relevant factors that can impact adherence and persistence to oral therapies among patients with HR+/HER2- early breast cancer, including patient perceptions and education, adverse events, care coordination, and collaboration
• Apply appropriate strategies to identify, treat, and monitor patients with HR+/HER2- early breast cancer receiving oral CDK4/6 inhibitor therapies to prevent/manage treatment- related adverse events (TRAEs)
• Integrate effective team-based communication approaches, including shared decision- making, to appropriately educate and engage patients on CDK4/6 inhibitors about TRAEs, collaboratively establish and achieve treatment goals, and maximize adherence and persistence

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
Sara M. Tolaney, MD, MPH
Chief, Division of Breast Oncology
Associate Director
Susan F. Smith Center for Women’s Cancers
Senior Physician
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Sara M. Tolaney, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for ARC Therapeutics; AstraZeneca; Athenex, Inc.; BeyondSpring Pharmaceuticals Inc.; Blueprint Medicines; Bristol Myers Squibb; Certara, USA; Chugai Pharmaceutical Co., Ltd.; CytomX Therapeutics, Inc.; Daiichi Sankyo Inc.; Eisai Inc.; Ellipses Pharma; 4D pharma; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Infinity Therapeutics; Lilly; Merck & Co., Inc.; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Odonate Therapeutics, Inc; OncoSec Medical Incorporated; OncXerna Therapeutics, Inc.; Pfizer; Reveal Genomics; sanofi-aventis U.S. LLC; Seattle Genetics, Inc.; Zentalis; and Zymeworks Inc.
Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Cyclacel Pharmaceuticals, Inc.; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; NanoString Technologies Inc.; Nektar; Novartis Pharmaceuticals Corporation; Pfizer; sanofi-aventis U.S. LLC; and Seattle Genetics, Inc.

Co-Chair/Planner
Elahe Salehi, DNP, ANP-BC
Breast Oncology Center
Dana-Farber Cancer Institute
Director of Advanced Practice Nursing
Division of Women’s Cancers
Boston, Massachusetts

Elahe Salehi, DNP, ANP-BC, has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit^TM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

This activity expired on October 16, 2023; credit is no longer available.

Breaking Down Barriers to Treatment Adherence and Persistence in HR+/HER2- Early Breast Cancer

Media: Enduring Material
Activity Release Date: October 17, 2022
Activity Expiration Date: October 16, 2023
Time to Complete Activity: 60 minutes

Activity Description

Oral anticancer therapies, including CDK4/6 inhibitors, are well established in the treatment of HR+/HER2- advanced breast cancer and, with the recent approval of abemaciclib for the treatment of HR+/HER2- early breast cancer, have now moved into earlier disease settings. This activity features strategies for risk assessment and individualized treatment selection for patients with HR+/HER2- early breast cancer, as well as best practices for improving adherence and persistence to ensure patients stay on prescribed therapy by providing patient education, guidance, and appropriately monitoring and managing treatment-related adverse events.

Target Audience

This activity has been designed to meet the educational needs of oncologists, oncology staff nurses, advanced practice nurses, nurse navigators, and other care team professionals who manage patients with HR+/HER2- early breast cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Review the mechanism of action, latest safety and efficacy data, and clinical role of currently approved CDK4/6 inhibitors in HR+/HER2- early breast cancer
• Describe disease-, treatment-, management-, patient-related, and other relevant factors that can impact adherence and persistence to oral therapies among patients with HR+/HER2- early breast cancer, including patient perceptions and education, adverse events, care coordination, and collaboration
• Apply appropriate strategies to identify, treat, and monitor patients with HR+/HER2- early breast cancer receiving oral CDK4/6 inhibitor therapies to prevent/manage treatment- related adverse events (TRAEs)
• Integrate effective team-based communication approaches, including shared decision- making, to appropriately educate and engage patients on CDK4/6 inhibitors about TRAEs, collaboratively establish and achieve treatment goals, and maximize adherence and persistence

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
Sara M. Tolaney, MD, MPH
Chief, Division of Breast Oncology
Associate Director
Susan F. Smith Center for Women’s Cancers
Senior Physician
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Sara M. Tolaney, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for ARC Therapeutics; AstraZeneca; Athenex, Inc.; BeyondSpring Pharmaceuticals Inc.; Blueprint Medicines; Bristol Myers Squibb; Certara, USA; Chugai Pharmaceutical Co., Ltd.; CytomX Therapeutics, Inc.; Daiichi Sankyo Inc.; Eisai Inc.; Ellipses Pharma; 4D pharma; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Infinity Therapeutics; Lilly; Merck & Co., Inc.; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Odonate Therapeutics, Inc; OncoSec Medical Incorporated; OncXerna Therapeutics, Inc.; Pfizer; Reveal Genomics; sanofi-aventis U.S. LLC; Seattle Genetics, Inc.; Zentalis; and Zymeworks Inc.
Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Cyclacel Pharmaceuticals, Inc.; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; NanoString Technologies Inc.; Nektar; Novartis Pharmaceuticals Corporation; Pfizer; sanofi-aventis U.S. LLC; and Seattle Genetics, Inc.

Co-Chair/Planner
Elahe Salehi, DNP, ANP-BC
Breast Oncology Center
Dana-Farber Cancer Institute
Director of Advanced Practice Nursing
Division of Women’s Cancers
Boston, Massachusetts

Elahe Salehi, DNP, ANP-BC, has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit^TM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

This activity expired on October 6, 2023; credit is no longer available.

Toward a Goal of Breathing Easy: Identifying Which of Your Patients With Chronic Rhinosinusitis With Nasal Polyps Can Benefit From Targeted Biologic Therapy

Media: Enduring Material
Activity Release Date: October 7, 2022
Activity Expiration Date: October 6, 2023
Time to Complete Activity: 60 minutes

Activity Description

Chronic rhinosinusitis with nasal polyps (CRSwNP) is one phenotype of CRS that is driven by type 2 inflammation and is particularly difficult to manage, especially when it occurs comorbidly with asthma, as is the case in up to 60% of patients with CRSwNP. However, biological agents that target type 2 inflammation and are already approved for other indications (eg, asthma, atopic dermatitis) have begun to emerge as available therapeutic options for CRSwNP.

In this activity, Dr. Anju T. Peters shares her expertise in optimal clinical decision-making for patients with CRSwNP that is based on the latest evidence, best practice recommendations, and effective interdisciplinary collaboration.

Target Audience

This activity has been designed to meet the educational needs of physicians, nurses, pharmacists, and other clinicians involved in the care of patients with nasal polyps.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Identify patients with severe, inadequately controlled CRSwNP who would derive benefit from targeted biologic therapy
• Assess patients with CRSwNP for comorbid conditions such as asthma and atopic dermatitis based on the relationship between CRSwNP and other type 2 inflammatory disorders
• Employ a multidisciplinary approach to the treatment of patients with CRSwNP according to practice guidelines and the latest clinical evidence

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Anju T. Peters, MD, MS
Professor of Medicine,
Director of Clinical Research
Division of Allergy and Immunology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Anju T. Peters, MD, MS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; GlaxoSmithKline; OptiNose US, Inc.; and Sanofi/Regeneron Pharmaceuticals Inc.
Grant/Research Support from AstraZeneca; OptiNose US, Inc.; and Sanofi/Regeneron Pharmaceuticals Inc.

Patient/Planner
Rhonda Nelson

Rhonda Nelson has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Certification Statement

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.8 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-039-H01-P
Type of Activity: Knowledge

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with confirmation of submission to CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

This activity expired on October 6, 2023; credit is no longer available.

Toward a Goal of Breathing Easy: Identifying Which of Your Patients With Chronic Rhinosinusitis With Nasal Polyps Can Benefit From Targeted Biologic Therapy

Media: Enduring Material
Activity Release Date: October 7, 2022
Activity Expiration Date: October 6, 2023
Time to Complete Activity: 60 minutes

Activity Description

Chronic rhinosinusitis with nasal polyps (CRSwNP) is one phenotype of CRS that is driven by type 2 inflammation and is particularly difficult to manage, especially when it occurs comorbidly with asthma, as is the case in up to 60% of patients with CRSwNP. However, biological agents that target type 2 inflammation and are already approved for other indications (eg, asthma, atopic dermatitis) have begun to emerge as available therapeutic options for CRSwNP.

In this activity, Dr. Anju T. Peters shares her expertise in optimal clinical decision-making for patients with CRSwNP that is based on the latest evidence, best practice recommendations, and effective interdisciplinary collaboration.

Target Audience

This activity has been designed to meet the educational needs of physicians, nurses, pharmacists, and other clinicians involved in the care of patients with nasal polyps.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Identify patients with severe, inadequately controlled CRSwNP who would derive benefit from targeted biologic therapy
• Assess patients with CRSwNP for comorbid conditions such as asthma and atopic dermatitis based on the relationship between CRSwNP and other type 2 inflammatory disorders
• Employ a multidisciplinary approach to the treatment of patients with CRSwNP according to practice guidelines and the latest clinical evidence

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Anju T. Peters, MD, MS
Professor of Medicine,
Director of Clinical Research
Division of Allergy and Immunology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Anju T. Peters, MD, MS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; GlaxoSmithKline; OptiNose US, Inc.; and Sanofi/Regeneron Pharmaceuticals Inc.
Grant/Research Support from AstraZeneca; OptiNose US, Inc.; and Sanofi/Regeneron Pharmaceuticals Inc.

Patient/Planner
Rhonda Nelson

Rhonda Nelson has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Certification Statement

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.8 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-039-H01-P
Type of Activity: Knowledge

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with confirmation of submission to CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

This activity expired on October 28, 2023; credit is no longer available.

The Power of Personalized Medicine in AML: Linking Individualized Treatment to Enhanced Patient Outcomes

Media: Enduring Material
Activity Release Date: September 29, 2022
Activity Expiration Date: October 28, 2023
Time to Complete Activity: 60 minutes

Activity Description

Are you up on the most recent therapeutic breakthroughs for personalized care in acute myeloid leukemia (AML)? PeerView’s latest Clinical Consults AML program, based on a live event, brings you insights from experts on the power of modern personalized medicine. Using case-based examples and the latest data, the experts will demonstrate how to integrate novel intensive therapies, targeted agents, and maintenance strategies into clinical management while showcasing best practices from leading cancer centers to provide guidance on how innovative therapies can be safely used to re-invent AML management protocols.

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, oncologists, nurses, pharmacists, advanced practice clinicians, and other healthcare professionals involved in the care of patients with AML.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Cite updated clinical findings on novel cytotoxic, targeted, epigenetic, and immune-based strategies (including combination therapies) with applications in acute myeloid leukemia (AML) care—including in the newly diagnosed (ND), post-remission maintenance, or relapsed/refractory (R/R) settings
• Incorporate novel therapeutics into personalized, team-based management of ND and R/R AML based on factors such as age, fitness, treatment history, depth of response, HCT eligibility, and the presence or absence of genetic/molecular features
• Develop team-based strategies to address the unique suite of adverse events associated with the use of novel therapeutics for AML

Accreditation, Support, and Credit

In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through independent medical education grants from AbbVie, Bristol Myers Squibb, Daiichi Sankyo, Inc., and Jazz Pharmaceuticals.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Continuing Pharmacy Education

Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-102-H01-P
Type of Activity: Application

Faculty Disclosures

Co-Chair/Planner
Naval Daver, MD
Director, Leukemia Research Alliance Program
Associate Professor
Department of Leukemia, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Naval Daver, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Agios Pharmaceuticals, Inc.; Amgen Inc.; AROG Pharmaceuticals, INC.; Astellas Pharma Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; Genentech, Inc.; Gilead Sciences, Inc.; ImmunoGen, Inc.; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Servier Pharmaceuticals LLC; Shattuck Labs, Inc.; Syndax Pharmaceuticals, Inc.; and Trillium Therapeutics Inc.
Grant/Research Support from AbbVie Inc.; Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Fate Therapeutics; Genentech, Inc.; Gilead Sciences, Inc.; GlycoMimetics, Inc.; Hanmi Pharmaceutical Co., Ltd.; ImmunoGen, Inc.; NovImmune SA; Pfizer Inc.; Servier Pharmaceuticals LLC; Trillium Therapeutics Inc.; and TrovaGene, Inc. Research funding goes to institution.

Co-Chair/Planner
Amir T. Fathi, MD
Program Director, Center for Leukemia
Massachusetts General Hospital Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Amir T. Fathi, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Agios Pharmaceuticals, Inc./Servier Pharmaceuticals LLC.; Amgen Inc.; Astellas Pharma Inc.; Blueprint Medicines Corporation; Celgene Corporation/Bristol Myers Squibb; EnClear Therapies; Foghorn Therapeutics; Forma Therapeutics; Genentech, Inc.; ImmunoGen, Inc.; Ipsen Pharma; Kite Pharma; Kura Oncology, Inc.; Mablytics; MorphoSys AG; Novartis Pharmaceuticals Corporation; Orum; PureTech Health; and Takeda Pharmaceutical Company Ltd.
Grant/Research Support from AbbVie Inc.; Agios Pharmaceuticals, Inc./Servier Pharmaceuticals LLC.; and Celgene Corporation/Bristol Myers Squibb.

All of the relevant financial relationships listed have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

For pharmacists, upon receipt of the completed activity evaluation, you will receive an email from email@email.peerviewpress.com within 2 weeks. MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

This activity expired on October 28, 2023; credit is no longer available.

The Power of Personalized Medicine in AML: Linking Individualized Treatment to Enhanced Patient Outcomes

Media: Enduring Material
Activity Release Date: September 29, 2022
Activity Expiration Date: October 28, 2023
Time to Complete Activity: 60 minutes

Activity Description

Are you up on the most recent therapeutic breakthroughs for personalized care in acute myeloid leukemia (AML)? PeerView’s latest Clinical Consults AML program, based on a live event, brings you insights from experts on the power of modern personalized medicine. Using case-based examples and the latest data, the experts will demonstrate how to integrate novel intensive therapies, targeted agents, and maintenance strategies into clinical management while showcasing best practices from leading cancer centers to provide guidance on how innovative therapies can be safely used to re-invent AML management protocols.

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, oncologists, nurses, pharmacists, advanced practice clinicians, and other healthcare professionals involved in the care of patients with AML.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Cite updated clinical findings on novel cytotoxic, targeted, epigenetic, and immune-based strategies (including combination therapies) with applications in acute myeloid leukemia (AML) care—including in the newly diagnosed (ND), post-remission maintenance, or relapsed/refractory (R/R) settings
• Incorporate novel therapeutics into personalized, team-based management of ND and R/R AML based on factors such as age, fitness, treatment history, depth of response, HCT eligibility, and the presence or absence of genetic/molecular features
• Develop team-based strategies to address the unique suite of adverse events associated with the use of novel therapeutics for AML

Accreditation, Support, and Credit

In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through independent medical education grants from AbbVie, Bristol Myers Squibb, Daiichi Sankyo, Inc., and Jazz Pharmaceuticals.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Continuing Pharmacy Education

Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-102-H01-P
Type of Activity: Application

Faculty Disclosures

Co-Chair/Planner
Naval Daver, MD
Director, Leukemia Research Alliance Program
Associate Professor
Department of Leukemia, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Naval Daver, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Agios Pharmaceuticals, Inc.; Amgen Inc.; AROG Pharmaceuticals, INC.; Astellas Pharma Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo Co., Ltd.; Genentech, Inc.; Gilead Sciences, Inc.; ImmunoGen, Inc.; Jazz Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Servier Pharmaceuticals LLC; Shattuck Labs, Inc.; Syndax Pharmaceuticals, Inc.; and Trillium Therapeutics Inc.
Grant/Research Support from AbbVie Inc.; Amgen Inc.; Astellas Pharma Inc.; Bristol Myers Squibb; Daiichi Sankyo Co., Ltd.; Fate Therapeutics; Genentech, Inc.; Gilead Sciences, Inc.; GlycoMimetics, Inc.; Hanmi Pharmaceutical Co., Ltd.; ImmunoGen, Inc.; NovImmune SA; Pfizer Inc.; Servier Pharmaceuticals LLC; Trillium Therapeutics Inc.; and TrovaGene, Inc. Research funding goes to institution.

Co-Chair/Planner
Amir T. Fathi, MD
Program Director, Center for Leukemia
Massachusetts General Hospital Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Amir T. Fathi, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Agios Pharmaceuticals, Inc./Servier Pharmaceuticals LLC.; Amgen Inc.; Astellas Pharma Inc.; Blueprint Medicines Corporation; Celgene Corporation/Bristol Myers Squibb; EnClear Therapies; Foghorn Therapeutics; Forma Therapeutics; Genentech, Inc.; ImmunoGen, Inc.; Ipsen Pharma; Kite Pharma; Kura Oncology, Inc.; Mablytics; MorphoSys AG; Novartis Pharmaceuticals Corporation; Orum; PureTech Health; and Takeda Pharmaceutical Company Ltd.
Grant/Research Support from AbbVie Inc.; Agios Pharmaceuticals, Inc./Servier Pharmaceuticals LLC.; and Celgene Corporation/Bristol Myers Squibb.

All of the relevant financial relationships listed have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

For pharmacists, upon receipt of the completed activity evaluation, you will receive an email from email@email.peerviewpress.com within 2 weeks. MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

This activity expired on October 28, 2023; credit is no longer available.

Progress on the Path to Better Outcomes in RRMM: Expert Perspectives on the Further Integration of BCMA-Directed Antibodies and Cellular Therapies

Media: Enduring Material
Activity Release Date: September 29, 2022
Activity Expiration Date: October 28, 2023
Time to Complete Activity: 60 minutes

Activity Description

This “MasterClass & Case Forum” program utilizes a linked foundational lecture and case-based approach to highlight recent advances with B-cell maturation antigen (BCMA)–targeted therapies and illustrate their effects on outcomes in relapsed/refractory multiple myeloma (RRMM). Each case-centered session includes an assessment of the relevant evidence supporting the use of BCMA-directed antibodies and CAR-T therapy. Expert-led, case-based instruction on patient assessment, therapy selection, dosing and scheduling, and management of unique treatment-related AEs is built on this foundation. Watch today to earn credit!

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, oncologists, nurses, pharmacists, advanced practice clinicians, and other clinicians involved in the care of patients with multiple myeloma.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Summarize the latest evidence supporting the treatment roles of novel BCMA-targeting platforms, including ADCs, bispecifics, and CAR-T therapy, in relapsed/refractory disease
• Develop evidence-based regimens with novel BCMA/ADCs, bispecifics, and cellular approaches that are informed by factors such as patient preference, disease prognosis, and functional status, among others
• Manage practical aspects of BCMA-targeted therapy, including appropriate dosing/scheduling; patient counseling; and unique safety considerations, such as cytopenias, infusion-related events, ocular toxicity, and CRS, among others

Accreditation, Support, and Credit

In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This educational activity is supported through independent medical education grants from Bristol Myers Squibb, GlaxoSmithKline, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Regeneron Pharmaceuticals, Inc.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Continuing Pharmacy Education

Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-103-H01-P
Type of Activity: Application

Faculty Disclosures

Co-Chair/Planner
Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Sagar Lonial, MD, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Amgen; Bristol Myers Squibb; Celgene Corporation; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Takeda Pharmaceutical Company Limited.
Stock Shareholder in TG Therapeutics.

Co-Chair/Planner
Krina Patel, MD, MSc
Associate Professor
Center Medical Director
The University of Texas MD Anderson Cancer Center
Houston, Texas

Krina Patel, MD, MSc, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Arcellx; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Karyopharm; Legend Biotech USA Inc.; Merck & Co., Inc.; Oncopeptides, Inc.; and Pfizer.
Grant/Research Support from Allogene Therapeutics; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Nektar; Precision BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

All of the relevant financial relationships listed have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

For pharmacists, upon receipt of the completed activity evaluation, you will receive an email from email@email.peerviewpress.com within 2 weeks. MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

This activity expired on October 28, 2023; credit is no longer available.

Progress on the Path to Better Outcomes in RRMM: Expert Perspectives on the Further Integration of BCMA-Directed Antibodies and Cellular Therapies

Media: Enduring Material
Activity Release Date: September 29, 2022
Activity Expiration Date: October 28, 2023
Time to Complete Activity: 60 minutes

Activity Description

This “MasterClass & Case Forum” program utilizes a linked foundational lecture and case-based approach to highlight recent advances with B-cell maturation antigen (BCMA)–targeted therapies and illustrate their effects on outcomes in relapsed/refractory multiple myeloma (RRMM). Each case-centered session includes an assessment of the relevant evidence supporting the use of BCMA-directed antibodies and CAR-T therapy. Expert-led, case-based instruction on patient assessment, therapy selection, dosing and scheduling, and management of unique treatment-related AEs is built on this foundation. Watch today to earn credit!

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, hematologists, oncologists, nurses, pharmacists, advanced practice clinicians, and other clinicians involved in the care of patients with multiple myeloma.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Summarize the latest evidence supporting the treatment roles of novel BCMA-targeting platforms, including ADCs, bispecifics, and CAR-T therapy, in relapsed/refractory disease
• Develop evidence-based regimens with novel BCMA/ADCs, bispecifics, and cellular approaches that are informed by factors such as patient preference, disease prognosis, and functional status, among others
• Manage practical aspects of BCMA-targeted therapy, including appropriate dosing/scheduling; patient counseling; and unique safety considerations, such as cytopenias, infusion-related events, ocular toxicity, and CRS, among others

Accreditation, Support, and Credit

In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This educational activity is supported through independent medical education grants from Bristol Myers Squibb, GlaxoSmithKline, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Regeneron Pharmaceuticals, Inc.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Continuing Pharmacy Education

Medical Learning Institute, Inc. designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-22-103-H01-P
Type of Activity: Application

Faculty Disclosures

Co-Chair/Planner
Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Sagar Lonial, MD, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Amgen; Bristol Myers Squibb; Celgene Corporation; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis Pharmaceuticals Corporation; and Takeda Pharmaceutical Company Limited.
Stock Shareholder in TG Therapeutics.

Co-Chair/Planner
Krina Patel, MD, MSc
Associate Professor
Center Medical Director
The University of Texas MD Anderson Cancer Center
Houston, Texas

Krina Patel, MD, MSc, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Arcellx; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Karyopharm; Legend Biotech USA Inc.; Merck & Co., Inc.; Oncopeptides, Inc.; and Pfizer.
Grant/Research Support from Allogene Therapeutics; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Nektar; Precision BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

All of the relevant financial relationships listed have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

For pharmacists, upon receipt of the completed activity evaluation, you will receive an email from email@email.peerviewpress.com within 2 weeks. MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.

About This CME/MOC/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

This activity expired on September 1, 2023; credit is no longer available.

Improving Clinical Care With Newer, Better Therapies for Targeting Actionable Gene Fusions in NSCLC

Media: Enduring Material
Activity Release Date: September 2, 2022
Activity Expiration Date: September 1, 2023
Time to Complete Activity: 60 minutes

Activity Description

In this activity, an expert in thoracic oncology discusses the expanding role of biomarker testing as well as current and emerging options for targeted treatment of fusion-positive NSCLC.

Target Audience

This activity has been designed to meet the educational needs of oncologists, pathologists, nurses, nurse practitioners, physician assistants, and other clinicians involved in the care of patients with NSCLC.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Describe the role of gene fusions, such as ALK, ROS1, NTRK, and RET, in the oncogenesis of NSCLC and the importance of detecting them in practice to inform treatment decisions
• Implement best practices for biomarker testing in NSCLC, including next generation sequencing and appropriate assays for detecting gene fusions, to identify patients with gene fusions who might benefit from targeted therapy
• Apply the latest evidence on targeted therapies for gene fusions to inform treatment decisions for patients with gene fusion–positive NSCLC
• Incorporate targeted therapies into individualized treatment plans for patients with gene fusion–positive NSCLC according to biomarker status, current evidence and guidelines, and patient needs, values, and preferences

Accreditation, Support, and Credit

In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals Inc., Genentech, a member of the Roche Group, Lilly, and Turning Point Therapeutics, Inc.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit^TM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Faculty Disclosures

Chair/Planner
Alexander Drilon, MD
Chief, Early Drug Development
Memorial Sloan Kettering Cancer Center
New York, New York

Alexander Drilon, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for 14ner Oncology, Inc./Elevation Oncology; AbbVie Inc.; Amgen Inc.; Applied Pharmaceutical Science; ArcherDX, Inc.; AstraZeneca; Axis Pharmaceuticals; BeiGene; BerGenBio ASA; Blueprint Medicines Corporation; Chugai Pharmaceutical Co., Ltd.; EMD Serono; Entos, Inc.; EPG Communication Holdings Ltd.; Exelixis, Inc.; Harborside; Helsinn Healthcare SA; Hengrui Therapeutics, Inc.; i3Health; Ignyta/Genentech, Inc./F. Hoffmann-La Roche Ltd.; Janssen Pharmaceuticals, Inc.; Liberum; Loxo Oncology/Bayer Corporation/Eli Lilly and Company; MBrace Therapeutics; Medendi Inc.; Merus; Monopteros Therapeutics; Monte Rosa Therapeutics; MORE Health, Inc.; Novartis Pharmaceuticals Corporation; Nuvalent; Ology Bioservices; Pfizer Inc.; Prelude Therapeutics; Remedica Ltd.; Repare Therapeutics; RV Pharma, LLC ; Takeda Pharmaceutical Company Limited/ARIAD Pharmaceuticals, Inc./Millennium Pharmaceuticals, Inc.; Touch Medical Media; Treeline Biosciences, Inc.; Turning Point Therapeutics, Inc.; Tyra Biosciences, Inc.; and Verastem, Inc.
Grant/Research Support from Foundation Medicine, Inc. *Paid to Institution: Exelixis, Inc.; GlaxoSmithKline; Pfizer Inc.; PharmaMar; Taiho Oncology, Inc; and Teva Pharmaceuticals USA, Inc.

All of the relevant financial relationships listed have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

About This CME/MOC/NCPD Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

This activity expired on September 1, 2023; credit is no longer available.

Improving Clinical Care With Newer, Better Therapies for Targeting Actionable Gene Fusions in NSCLC

Media: Enduring Material
Activity Release Date: September 2, 2022
Activity Expiration Date: September 1, 2023
Time to Complete Activity: 60 minutes

Activity Description

In this activity, an expert in thoracic oncology discusses the expanding role of biomarker testing as well as current and emerging options for targeted treatment of fusion-positive NSCLC.

Target Audience

This activity has been designed to meet the educational needs of oncologists, pathologists, nurses, nurse practitioners, physician assistants, and other clinicians involved in the care of patients with NSCLC.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Describe the role of gene fusions, such as ALK, ROS1, NTRK, and RET, in the oncogenesis of NSCLC and the importance of detecting them in practice to inform treatment decisions
• Implement best practices for biomarker testing in NSCLC, including next generation sequencing and appropriate assays for detecting gene fusions, to identify patients with gene fusions who might benefit from targeted therapy
• Apply the latest evidence on targeted therapies for gene fusions to inform treatment decisions for patients with gene fusion–positive NSCLC
• Incorporate targeted therapies into individualized treatment plans for patients with gene fusion–positive NSCLC according to biomarker status, current evidence and guidelines, and patient needs, values, and preferences

Accreditation, Support, and Credit

In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals Inc., Genentech, a member of the Roche Group, Lilly, and Turning Point Therapeutics, Inc.

Physician Continuing Medical Education

Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit^TM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nursing Continuing Professional Development

Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Faculty Disclosures

Chair/Planner
Alexander Drilon, MD
Chief, Early Drug Development
Memorial Sloan Kettering Cancer Center
New York, New York

Alexander Drilon, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for 14ner Oncology, Inc./Elevation Oncology; AbbVie Inc.; Amgen Inc.; Applied Pharmaceutical Science; ArcherDX, Inc.; AstraZeneca; Axis Pharmaceuticals; BeiGene; BerGenBio ASA; Blueprint Medicines Corporation; Chugai Pharmaceutical Co., Ltd.; EMD Serono; Entos, Inc.; EPG Communication Holdings Ltd.; Exelixis, Inc.; Harborside; Helsinn Healthcare SA; Hengrui Therapeutics, Inc.; i3Health; Ignyta/Genentech, Inc./F. Hoffmann-La Roche Ltd.; Janssen Pharmaceuticals, Inc.; Liberum; Loxo Oncology/Bayer Corporation/Eli Lilly and Company; MBrace Therapeutics; Medendi Inc.; Merus; Monopteros Therapeutics; Monte Rosa Therapeutics; MORE Health, Inc.; Novartis Pharmaceuticals Corporation; Nuvalent; Ology Bioservices; Pfizer Inc.; Prelude Therapeutics; Remedica Ltd.; Repare Therapeutics; RV Pharma, LLC ; Takeda Pharmaceutical Company Limited/ARIAD Pharmaceuticals, Inc./Millennium Pharmaceuticals, Inc.; Touch Medical Media; Treeline Biosciences, Inc.; Turning Point Therapeutics, Inc.; Tyra Biosciences, Inc.; and Verastem, Inc.
Grant/Research Support from Foundation Medicine, Inc. *Paid to Institution: Exelixis, Inc.; GlaxoSmithKline; Pfizer Inc.; PharmaMar; Taiho Oncology, Inc; and Teva Pharmaceuticals USA, Inc.

All of the relevant financial relationships listed have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

In order to receive credit, learners must participate in the entire CE activity. A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 70% or higher is needed to obtain MOC/CC credit (75% is required for ABS).

For nurses, the post-test and evaluation are required in their entirety and a score of 70% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) contact hours.

About This CME/MOC/NCPD Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

This activity expired on August 29, 2023; credit is no longer available.

Harmonizing Interprofessional Care With Modern, Molecularly Informed, and Equitable Therapy for Patients With Advanced Endometrial Cancer: Lessons From a Gynecologic Cancer Center of Excellence

Expert commentary is based on data presented at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting.

Media: Enduring Material
Activity Release Date: August 30, 2022
Activity Expiration Date: August 29, 2023
Time to Complete Activity: 30 minutes

Activity Description

In PeerView’s latest inExchange learning opportunity, experts from a gynecologic cancer center of excellence share the latest in modern, molecularly informed, and equitable therapy for EC using a team-based approach. They will share the rationale, science, and evidence behind novel therapies for recurrent and advanced EC, practical strategies to put these data into practice to develop individualized treatment plans, and interprofessional strategies supporting the safe and appropriate use of ICIs in community settings. Concluding with their perspectives on the future of treatment for recurrent and advanced EC—including the importance of diversifying clinical trial enrollment—this presentation is a quick, informative, and engaging chance to expand your knowledge and benefit your patients with EC.

Target Audience

This activity has been designed to meet the educational needs of gynecologic oncologists, medical oncologists, advanced practice clinicians, nurses, and other clinicians involved in the care of patients with endometrial cancer

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Describe the rationales, therapeutic roles, and key efficacy/safety evidence on novel and emerging therapies, including immuno-oncology treatments and innovative maintenance therapies, for subsets of patients with recurrent or advanced EC
• Develop contemporary, personalized management plans for patients with recurrent or advanced EC that incorporate new evidence and guideline recommendations, individual clinical and molecular features (eg, MMR/MSI phenotype), and patient goals and preferences
• Employ proactive, interprofessional team-based strategies to address practical aspects of novel therapies for recurrent or advanced EC, including adverse event management, patient education, and disparities in clinical care and research

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Ritu Salani, MD, MBA
Director, Division of Gynecologic Oncology
Professor, Department of Obstetrics and Gynecology
David Geffen School of Medicine at UCLA
Los Angeles, California

Ritu Salani, MD, MBA, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Arcus Biosciences, Inc.; GlaxoSmithKline; ImmunoGen, Inc.; Instil Bio; Merck & Co., Inc.; Mersana Therapeutics; Regeneron Pharmaceuticals; and Seagen Inc.
Grant/Research Support from Genentech.

Faculty/Planner
Rachel Frankenthal, MMS, PA-C, MPH
Physician Assistant
Division of Gynecologic Oncology
UCLA Medical Center
Los Angeles, California

Rachel Frankenthal, MMS, PA-C, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for ImmunoGen, Inc.
Speaker for Horizon CME and PCE Oncology Conference.

Support

This educational activity is supported by an educational grant from GlaxoSmithKline.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

This activity expired on August 29, 2023; credit is no longer available.

Harmonizing Interprofessional Care With Modern, Molecularly Informed, and Equitable Therapy for Patients With Advanced Endometrial Cancer: Lessons From a Gynecologic Cancer Center of Excellence

Expert commentary is based on data presented at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting.

Media: Enduring Material
Activity Release Date: August 30, 2022
Activity Expiration Date: August 29, 2023
Time to Complete Activity: 30 minutes

Activity Description

In PeerView’s latest inExchange learning opportunity, experts from a gynecologic cancer center of excellence share the latest in modern, molecularly informed, and equitable therapy for EC using a team-based approach. They will share the rationale, science, and evidence behind novel therapies for recurrent and advanced EC, practical strategies to put these data into practice to develop individualized treatment plans, and interprofessional strategies supporting the safe and appropriate use of ICIs in community settings. Concluding with their perspectives on the future of treatment for recurrent and advanced EC—including the importance of diversifying clinical trial enrollment—this presentation is a quick, informative, and engaging chance to expand your knowledge and benefit your patients with EC.

Target Audience

This activity has been designed to meet the educational needs of gynecologic oncologists, medical oncologists, advanced practice clinicians, nurses, and other clinicians involved in the care of patients with endometrial cancer

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Describe the rationales, therapeutic roles, and key efficacy/safety evidence on novel and emerging therapies, including immuno-oncology treatments and innovative maintenance therapies, for subsets of patients with recurrent or advanced EC
• Develop contemporary, personalized management plans for patients with recurrent or advanced EC that incorporate new evidence and guideline recommendations, individual clinical and molecular features (eg, MMR/MSI phenotype), and patient goals and preferences
• Employ proactive, interprofessional team-based strategies to address practical aspects of novel therapies for recurrent or advanced EC, including adverse event management, patient education, and disparities in clinical care and research

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Ritu Salani, MD, MBA
Director, Division of Gynecologic Oncology
Professor, Department of Obstetrics and Gynecology
David Geffen School of Medicine at UCLA
Los Angeles, California

Ritu Salani, MD, MBA, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Arcus Biosciences, Inc.; GlaxoSmithKline; ImmunoGen, Inc.; Instil Bio; Merck & Co., Inc.; Mersana Therapeutics; Regeneron Pharmaceuticals; and Seagen Inc.
Grant/Research Support from Genentech.

Faculty/Planner
Rachel Frankenthal, MMS, PA-C, MPH
Physician Assistant
Division of Gynecologic Oncology
UCLA Medical Center
Los Angeles, California

Rachel Frankenthal, MMS, PA-C, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for ImmunoGen, Inc.
Speaker for Horizon CME and PCE Oncology Conference.

Support

This educational activity is supported by an educational grant from GlaxoSmithKline.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

This activity expired on August 17, 2023; credit is no longer available.

Can Team-Based Care and Novel Therapies Improve Outcomes in Moderate to Severe Pediatric Atopic Dermatitis?

Media: Enduring Material
Activity Release Date: August 18, 2022
Activity Expiration Date: August 17, 2023
Time to Complete Activity: 60 minutes

Activity Description

In this activity, an expert in dermatology discusses team-based care and novel therapies in the treatment of pediatric patients with moderate to severe atopic dermatitis.

Target Audience

This activity has been designed to meet the educational needs of pediatricians, pediatric specialists in dermatology and allergy/immunology, primary care physicians, NPs, PAs, nurses, pharmacists, and other clinicians involved in the management of patients with atopic dermatitis.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Describe age-related and race-related differences in the phenotypic expression of atopic dermatitis (AD)
• Employ evidence-based strategies to determine disease impact and guide treatment decisions in pediatric patients with AD
• Discuss the rationale for targeting type 2 cytokines as a therapeutic approach in AD
• Assess clinical data on new and emerging treatment options for pediatric patients with moderate to severe AD
• Employ a team-based and patient-centered management approach to children and adolescents with atopic dermatitis to prevent flare-ups, identify comorbidities, maximize health-related quality of life, and recognize treatment-related side effects

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Robert Sidbury, MD, MPH
Professor, Department of Pediatrics
Chief, Division of Dermatology
Seattle Children's Hospital
University of Washington School of Medicine
Seattle, Washington

Robert Sidbury, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for LEO Pharma Inc.
Grant/Research Support from Galderma Laboratories, L.P.; Regeneron Pharmaceuticals Inc.; and UCB, Inc.
Speakers Bureau participant with Beiersdorf, Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1 MOC points in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

Continuing Certification Statement

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-033-H01-P
Type of Activity: Knowledge

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView

This activity expired on August 17, 2023; credit is no longer available.

Can Team-Based Care and Novel Therapies Improve Outcomes in Moderate to Severe Pediatric Atopic Dermatitis?

Media: Enduring Material
Activity Release Date: August 18, 2022
Activity Expiration Date: August 17, 2023
Time to Complete Activity: 60 minutes

Activity Description

In this activity, an expert in dermatology discusses team-based care and novel therapies in the treatment of pediatric patients with moderate to severe atopic dermatitis.

Target Audience

This activity has been designed to meet the educational needs of pediatricians, pediatric specialists in dermatology and allergy/immunology, primary care physicians, NPs, PAs, nurses, pharmacists, and other clinicians involved in the management of patients with atopic dermatitis.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Describe age-related and race-related differences in the phenotypic expression of atopic dermatitis (AD)
• Employ evidence-based strategies to determine disease impact and guide treatment decisions in pediatric patients with AD
• Discuss the rationale for targeting type 2 cytokines as a therapeutic approach in AD
• Assess clinical data on new and emerging treatment options for pediatric patients with moderate to severe AD
• Employ a team-based and patient-centered management approach to children and adolescents with atopic dermatitis to prevent flare-ups, identify comorbidities, maximize health-related quality of life, and recognize treatment-related side effects

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Robert Sidbury, MD, MPH
Professor, Department of Pediatrics
Chief, Division of Dermatology
Seattle Children's Hospital
University of Washington School of Medicine
Seattle, Washington

Robert Sidbury, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for LEO Pharma Inc.
Grant/Research Support from Galderma Laboratories, L.P.; Regeneron Pharmaceuticals Inc.; and UCB, Inc.
Speakers Bureau participant with Beiersdorf, Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1 MOC points in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

Continuing Certification Statement

Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-033-H01-P
Type of Activity: Knowledge

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView